To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Single-arm, Open-label, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06389006
• Other study ID #: RC48-C025
• Status: Recruiting
• Phase: Phase 2
• Start date: April 29, 2024
• Est. completion date: December 31, 2026

Study information

• Verified date: April 2024
• Source: RemeGen Co., Ltd.
• Contact: Leng Kang
• Phone: +8610-58075763
• Email: kang.leng[@]remegen.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Toripalimab sequential chemotherapy as in patients with HR-positive, HER2-low breast cancer

Description:

This is a single-arm, open-label, multicenter phase II clinical trial to evaluate the efficacy and safety of Disitamab Vedotin combined with Toripalimab sequential chemotherapy as neoadjuvant treatment in patients with HR-positive, HER2-low breast cancer

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 79
• Est. completion date: December 31, 2026
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Voluntarily agree to participate in the study and sign the informed consent;

2. Age =18 years old (including the threshold value);

3. Histologically confirmed invasive breast cancer with clinical stage T1c-T2(=2cm)cN1-2M0 or T3cN0-2M0;

4. As assessed by the research Center, the subjects can tolerate and plan to undergo radical surgery for breast cancer and have not previously received any anti-tumor systemic therapy for breast cancer;

5. Invasive breast tumor tissue with low HER2 expression confirmed by the central laboratory is defined as IHC 1+ or IHC 2+ expression of HER2 protein detected by immunohistochemistry (IHC), and no amplification detected by in situ hybridization (ISH) (according to the Breast Cancer HER2 Detection Guidelines 2019); Primary tumor specimens (wax pieces, slices or fresh tissues) can be provided for HER2 detection;

6. According to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2020 guidelines, tumor tissue estrogen receptor (ER) and progesterone receptor (PgR) expression = 1%;

7. Histological grade (Nottingham grading system) G3 or G2 with ER expression

8. ECOG physical status 0 or 1;

9. At least one measurable lesion according to RECIST v1.1 standard;

10. Heart function:

1. New York Heart Association (NYHA) Grade < 3;

2. left ventricular ejection fraction =50%;

11. Bone marrow or organ function should meet the following criteria within 7 days before the study dose: Hemoglobin = 90g/L; Absolute neutrophil count (ANC) =1.5×109/L; Platelet = 100 ×109/L; Serum total bilirubin = 1.5 times the upper limit of normal value (ULN); Aspartate aminotransferase (AST) and glutamic pyruvic transaminase (ALT) = 2.5 times the upper limit of normal value; International normalized ratio (INR) and activated partial thrombin time = 1.5×ULN; Serum creatinine = 1.5×ULN or creatinine clearance (CrCl) = 50 mL/min according to Cockcroft-Gault formula method;

12. Fertile female subjects who meet the following conditions

1. A serum pregnancy test (minimum sensitivity 25 mIU/mL or equivalent units of ß-human chorionic gonadotropin [ß-hCG]) must be negative within 72 hours before the first dosing of the study intervention. Subjects with false positive results who are confirmed not to be pregnant are eligible for study.

2. Must agree to contraception for the duration of the study and for at least 6 months after the last dose of investigational drug.

3. Must agree not to breastfeed or donate eggs from the time of signing the informed consent until 6 months after the last dose of investigational drug.

4. If sexually active and likely to result in pregnancy, continuous use of at least 2 acceptable forms of contraception, at least 1 of which must be highly effective from the time of the informed consent and continue until at least 6 months after the last dosing of the investigational drug.

13. Fertile male subjects who meet the following conditions

1. Must agree not to donate sperm from the time of signing the informed consent until at least 4 months after the last dose of investigational drug.

2. If sexual activity with a fertile person is likely to result in pregnancy, continuous use of at least 2 acceptable forms of contraception, at least 1 of which must be highly effective from the time of the informed consent and continue until at least 4 months after the last dosing of the investigational drug.

3. If sexually active with a pregnant or breastfeeding patient, condom use must continue from informed consent until at least 4 months after the last dosing of the investigational drug.

14. Able to understand trial requirements, willing and able to follow trial and follow-up procedures.

Exclusion Criteria:

1. Bilateral invasive breast cancer;

2. Previous history of invasive breast cancer;

3. Previously had carcinoma in situ of the breast and received adjuvant endocrine therapy within 5 years of surgery;

4. Use of the investigational drug or major surgery within 4 weeks prior to study dosing;

5. Have received or plan to receive live or attenuated vaccine within 4 weeks before the start of study dose;

6. Previous history of receiving allogeneic hematopoietic stem cell transplantation or organ transplantation;

7. Previous treatment with PD-(L)1, PD-L2, CTLA4 inhibitors and other Antibody-Drug Conjugates;

8. Uncontrolled or significant cardiovascular and cerebrovascular diseases

9. Presence of other treatable or serious lung diseases, including but not limited to active tuberculosis, interstitial lung disease, etc.;

10. Suffering from an active infection that requires systematic treatment;

11. Have active autoimmune diseases requiring systemic treatment within the past 2 years, allowing for relevant replacement therapy;

12. Have a clear past or present history of neurological or psychiatric disorders, including epilepsy or dementia;

13. Persistent = grade 2 sensory or motor neuropathy;

14. In the judgment of the investigator, there is a serious concomitant disease that endangers the safety of the subject or interferes with the completion of the clinical study;

15. Positive HIV test result; Patients with active hepatitis B or C; Persistent coronavirus (COVID-19) infection;

16. Known hypersensitivity or delayed anaphylaxis to certain components of Disitamab Vedotin, and Toripalimab or Certain components of chemotherapy drugs or similar drugs used in the study;

17. Suffering from another malignancy within 5 years prior to signing the informed consent

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Disitamab Vedotin for Injection
2.0mg/kg, intravenous infusion,D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed
• Toripalimab
3.0 mg/kg, intravenous infusion, D1, every 2 weeks, every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks,every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
• Epirubicin
According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed.
• Cyclophosphamide
According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks , Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed

Locations

Country	Name	City	State
China	Jiong Wu	Shanghai	Fudan University Shanghai Cancer Center

Sponsors (1)

Lead Sponsor	Collaborator
RemeGen Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total pathological complete response (tpCR) rate	Defined as the proportion of participants with a pathological assessment of pCR (ypT0/Tis, ypN0) in the analyzed population	1month after surgery
Secondary	Breast pathological complete response(bpCR)	Defined as the proportion of participants with a pathological assessment of bpCR in the analyzed population	1 month after surgery
Secondary	Event free survival (EFS)	The time from random assignment to disease progression, including local progression before surgery; disease recurrence-local, regional, distant, ipsilateral noninvasive, or contralateral (invasive or noninvasive)-or death from any cause	Up to approximately 3 or 5 years
Secondary	Disease-free survival (DFS)	From the date of surgery to the first local, regional, contralateral or distant recurrence, and death from any cause including 3- and 5-year event-free survival	Up to approximately 3 or 5 years
Secondary	Objective Response Rate (ORR)	Objective response rate.ORR assessed according to the evaluation criteria for the efficacy of solid tumors (RECIST 1.1)	Baseline to surgery
Secondary	Adverse events (AEs)	To evaluate safety including adverse event rate and adverse event grade	Up to approximately 2 months after surgery
Secondary	Change in cluster of differentiation 8 (CD8)	CD8 in tumor samples by biopsy at baseline and by surgery immediately after surgery would be evaluated by HE or immune staining.	At baseline to surgery
Secondary	Health-related quality of life - EORTC-QLQ-C30	Change from baseline in the physical functioning subscale of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) scores. Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden	Up to approximately 2 years
Secondary	Residual cancer burden score	According to the extent of the residual cancer in the primary breast cancer site (mm*mm), the residual cancer (mm*mm), cell density of residual cancer (%), proportion of carcinoma in situ (%), number of positive lymph nodes and maximum diameter of lymph node metastasis (mm), the RCB index and corresponding RCB classification can be obtained. The RCB index and the corresponding RCB grade can be obtained based on the maximum diameter of the cancer (mm).	1 month after surgery
Secondary	Change in tumor-infiltrating lymphocytes (TILs)	Defined as infiltrating lymphocytes isolated from tumor tissue.TILs in tumor samples by biopsy right before the first neoadjuvant therapy (baseline) and by surgery immediately after surgery would be evaluated by HE or immune staining.	At baseline to surgery
Secondary	Change in programmed cell death protein L1 (PD-L1)	PD1 in tumor samples by biopsy at baseline and by surgery immediately after surgery would be evaluated by HE or immune staining.	At baseline to surgery